Azactam


Also found in: Thesaurus, Medical.
ThesaurusAntonymsRelated WordsSynonymsLegend:
Noun1.Azactam - an antibiotic (trade name Azactam) used against severe infections; has minimal side effects
antibiotic, antibiotic drug - a chemical substance derivable from a mold or bacterium that can kill microorganisms and cure bacterial infections; "when antibiotics were first discovered they were called wonder drugs"
trademark - a formally registered symbol identifying the manufacturer or distributor of a product
References in periodicals archive ?
In the CABP trials, the comparator antibacterial treatment was Rocephin (ceftriaxone) and in the ABSSSI trials, the comparator antibacterial treatment was Vancocin (vancomycin) plus Azactam (aztreonam).
We have about 600 employees working at the BMS complex in Humacao manufacturing other key company products such as Avapro, Monopril, Pravachol, Corgard, Zerit, Azactam, Serzone, and its best-selling diabetes treatment drug, Glucophage.
Elan ceased distributing Azactam and Maxipime in 2010.
Elan ceased distributing Azactam as of March 31, 2010, and Maxipime as of September 30, 2010.
Squibb & Sons directing Phase I - IV studies of Azactam leading to its worldwide registration.
The increase was primarily due to the 20% growth in global in-market net sales of Tysabri, which more than offset the cessation of revenues from Azactam, Prialt and Maxipime.
Though script growth of certain drugs continues to be impressive, in particular for antibiotics Maxipime and Azactam, Zanaflex for spasticity, and Skelaxin for musculoskeletal pain, we are cautious with regard to growth of recently approved Myobloc for cervical dystonia due to its potentially cumbersome label," said Hazlett.
The increased gross margin principally reflects higher sales of Tysabri and the Ampyra launch, which more than offset lower revenues from Maxipime, Azactam, Skelaxin and Prialt.
5 million operating loss before the net gain on divestment of business and other net charges recorded by the BioNeurology business in the third quarter of 2009, and reflects the continued growth in Tysabri revenues offsetting the expected reduced revenues from Azactam and Prialt, in addition to a 16% reduction in combined SG&A and R&D expenses.
In assessing the first half performance, it is important to note that these results were achieved against a background where we have, as expected, seen reduced revenues from a number of products including Azactam and Prialt([R]) in the BioNeurology business and Skelaxin([R]) and Tricor([R]) in the Elan Drug Technologies (EDT) business, as well as an increased investment in development activities related particularly to Tysabri, ELND005 and the EDT business.
The increased gross margin principally reflects higher sales of Tysabri, which more than offset lower gross margins on Maxipime, Azactam and the EDT business.
The increase was primarily due to solid growth in Tysabri sales, which more than compensated for reduced sales of Azactam and Maxipime.